SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Abiomed, Inc. (Nasdaq – ABMD)

BALA CYNWYD – November 1, 2022 /Globe Newswire/ – Law office of Brodsky & Smith announces that it is investigating potential claims against the Board of Directors of Abiomed, Inc. (“Abiomed” or the “Company”) (Nasdaq – ABMD) for possible breaches of fiduciary duty and other violations of federal and state law in connection with the Company’s agreement to be acquired by Johnson & Johnson (“J&J”) (NYSE – JNJ). Under the terms of the Merger Agreement, J&J will pay $380.00 a share in cash for all outstanding shares of Abiomed. The deal has an enterprise value of $16.6 billion. Abiomed shareholders will also receive a non-tradeable contingent value right entitling the holder to receive up to $35.00 per share in cash if certain commercial and clinical milestones are achieved.

The investigation concerns whether the Abiomed Board breached its fiduciary duties to shareholders by failing to conduct a fair process, and whether J&J is paying too little for the Company.

If you own shares of Abiomed stock and wish to discuss the legal ramifications of the investigation, or have any questions, you may e-mail or call the law office of Brodsky & Smith who will, without obligation or cost to you, attempt to answer your questions. You may contact Jason L. Brodsky, Esquire, or Marc L. Ackerman, Esquire at Brodsky & Smith, Two Bala Plaza, Suite 805, Bala Cynwyd, PA 19004, or call toll free 855-576-4847.

Brodsky & Smith is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.